Alf Lindberg joins Serendipity Innovations’ board of directors

- With his experience of developing one of the world's largest vaccines, being secretary of the Nobel Committee within medicine and working as head of research for two large pharmaceutical companies, Alf's presence and knowledge is valuable to us, says Ashkan Pouya, Chairman of the Board at Serendipity Innovations.

Alf has extensive experience in both research and the industrial sector. He has been professor and chairman of the department of clinical bacteriology at the Karolinska Institute, as well as CSO and head of research for Wyeth Vaccines and Sanofi Pasteur. Alf was in charge of the effort to develop the world's first blockbuster vaccine, Prevnar. Besides his involvement in Serendipity Innovations, Alf is a board member of several biotech firms and scientific advisory boards.

- Over the course of the last two years, I have been an adviser to Serendipity Innovations and some of the companies in its portfolio. I have, during this time, gained good insights into the operations and its widespread opportunities, and I am now looking forward to pursuing a more active and formal role in creating value, says Alf Lindberg.

The other members of Serendipity Innovations' Board of Directors are Cecilia Gunne, Anders Wall, Bengt-Arne Vedin and Ashkan Pouya.

Stockholm, 11 September 2012

For more information, please contact:

Serendipity Innovations AB is a venture capital company specialized in building new, innovative technology companies based on academic research and other knowledge intensive environments. The portfolio consists of 14 companies operating in five sectors: clean-tech, life science, materials technology, IT and medical technology.

For more information:

Omid Ekhlasi, Chief Communications Officer Serendipity Innovations


Tel: +45 (0) 73-5252509